Article Details
Retrieved on: 2024-04-22 21:56:37
Tags for this article:
Click the tags to see associated articles and topics
Summary
Eli Lilly's acquisition of a Wisconsin drug plant aims to boost its biopharma manufacturing capacity, possibly for its obesity and diabetes medications like Zepbound and Mounjaro, amidst growing demand and current shortages. This move parallels Novo Nordisk's expansion through its deal with Catalent for additional GLP-1 medicine production.
Article found on: www.biopharmadive.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here